The complaint filed against the New York-based pharmaceutical firm alleges that Zoetis issued false and misleading statements concerning the market viability and performance of key products, including Librela, Apoquel, and Cytopoint. These claims suggest the company failed to accurately disclose internal challenges facing these flagship therapies during the specified class period.
Legal counsel from the DJS Law Group is currently soliciting shareholders to serve as lead plaintiffs in the action. While the deadline for filing motions to act as lead plaintiff is set for July 27, 2026, the firm notes that individual investors are not required to hold a lead role to potentially participate in any future recovery. The lawsuit specifically cites violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Comments (0)
No comments yet. Be the first!